---
schema_version: "secwatch.filing_event.v1"
accession: "0001434647-26-000067"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2026-08-05T20:13:22+00:00"
generated_at: "2026-08-05T20:14:09.578851+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zevra Q2 2026 net revenue $39.7M, up 53% YoY; MIPLYFFA drives growth

## Summary
- Net revenue $39.7M, including $30.2M from MIPLYFFA; up from $25.9M in Q2 2025.
- Net income $8.8M ($0.14 per share); adjusted net income $15.2M ($0.25 per share).
- Cash, cash equivalents and investments $260.2M as of June 30, 2026.
- 14 MIPLYFFA prescription enrollment forms in Q2; total 184 since launch; 69% covered lives.
- 66 patients enrolled in Phase 3 DiSCOVER trial for celiprolol; EU MAA re-examination requested.

## SEC filing metadata
- accession: 0001434647-26-000067
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2026-08-05T20:13:22+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000067/0001434647-26-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143464726000067/zvra-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001434647-26-000067
- JSON: https://secwatch.observer/filing/0001434647-26-000067.json
- Plain text: https://secwatch.observer/filing/0001434647-26-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.